SCHEMBL25754943

SCHEMBL25754943

CNC(=O)CCCCOCCCc1nc[nH]n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 2/20 0.38
PDE3A Q14432 2/20 0.38
P2RY12 Q9H244 1/20 0.38
GAA P10253 1/20 0.38
PDK2 Q15119 1/20 0.34
MPO P05164 1/20 0.34
TBXAS1 P24557 1/20 0.33
HDAC1 Q13547 3/20 0.33
HDAC2 Q92769 2/20 0.33
MTNR1A P48039 2/20 0.32
MTNR1B P49286 1/20 0.32
CNR1 P21554 4/20 0.32
CNR2 P34972 4/20 0.32
DEGS1 O15121 1/20 0.32
MEN1 O00255 1/20 0.31
ALPL P05186 1/20 0.31
ALPI P09923 1/20 0.31
ALPG P10696 1/20 0.31
KMT2A Q03164 1/20 0.31
HDAC3 O15379 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754944 0.93 GAA (0.40) PDE3BPDE3AP2RY12GAAPDK2
SCHEMBL25754946 0.88 TBXAS1 (0.41) PDE3BPDE3AP2RY12MPOTBXAS1
SCHEMBL25755263 0.87 PDE3B (0.33) PDE3BPDE3AP2RY12MTNR1AMTNR1B
SCHEMBL25755270 0.83 KDM4E (0.32)
SCHEMBL25755259 0.83 KDM4E (0.37) GAA
SCHEMBL25755267 0.82 PDE3B (0.35) PDE3BPDE3AP2RY12MTNR1AMTNR1B
SCHEMBL25755261 0.79 LTA4H (0.34) PDE3BPDE3AP2RY12GAA
SCHEMBL25754952 0.78 PDE3B (0.34) PDE3BPDE3AP2RY12GAAPDK2
SCHEMBL25755257 0.78 ALDH1A1 (0.32) PDE3BPDE3AP2RY12MEN1KMT2A
SCHEMBL25755271 0.77 KDM4E (0.37) PDE3BPDE3AP2RY12GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 PDE3B 4816/4885PDE3A 4814/4885P2RY12 4844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.